Asset profile
VTX3232
Small molecule
Evidence outlook · lead readout
NCT06771115 · Obesity
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT06771115: Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Because the trial’s outcome is currently unknown, the evidence remains limited despite its controlled design.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Parkinson's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
126 competitors in this universe: 3 direct rivals (same mechanism and indication), 3 same-class, 120 same-indication; 89 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| VTX3232: this drug | Phase 2 | Small molecule | NLRP3 inflammasome, NLRP3 | ||
| NT-0796 | Phase 2 | Small molecule | NLRP3 inflammasome | ||
| VENT-02 | Phase 1/2 | Small molecule | NLRP3 | ||
| HL-400 | Phase 1 | Small molecule | NLRP3 | ||
| ABP-745 | Phase 2 | Small molecule | NLRP3 inflammasome | ||
| AZD4144 | Phase 2 | Small molecule | NLRP3 inflammasome | ||
| Selnoflast | Phase 2 | Small molecule | NLRP3 inflammasome | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Entacapone (Comtess) | Approved | Small molecule | COMT | ||
| Foslevodopa / Foscarbidopa (Vyalev) | Approved | Small molecule | dopamine precursor | ||
| Inbrija (CVT-301) | Approved | Small molecule | dopamine precursor | ||
| Istradefylline (Nourianz) | Approved | Small molecule | adenosine A2A | ||
| Levodopa-Carbidopa Intestinal Gel (Duopa) | Approved | Small molecule | dopamine precursor |
…and 111 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.